In this issue:
Palbociclib for hormone-receptor+, HER2+ advanced breast cancer
Sacituzumab govitecan + pembrolizumab for advanced TNBC
TDP for HER2+ metastatic breast cancer
PROs for SERENA-6: camizestrant + CDK4/6 inhibitor in advanced ESR1-mutated breast cancer
Camizestrant + capivasertib for oestrogen receptor+, HER2– advanced breast cancer
Chemotherapy in lymph node-negative invasive papillary breast cancer
Extended endocrine therapy after adjuvant LHRH in premenopausal node+, hormone receptor+ breast cancer
Adding ipatasertib to dual anti-HER2 maintenance in PIK3CA-mutated HER2+ metastatic breast cancer
Sapacitabine + olaparib in BRCA1/2-mutated metastatic breast cancer
Neoadjuvant trastuzumab deruxtecan alone or followed by THP for high-risk HER2+ early breast cancer
Please login below to download this issue (PDF)